maybe:price being held down so CG and GP can get their options @...

First 14 Last

Share
Profile

Follow
itsagas

13,140 Posts.

1376

05/10/21

08:34

Post #: 56561306
Share

Originally posted by dalts66: ↑

I think you have written what most are thinking. Its been some time since we had the Phase 2 data, and things seemed to be going well with the rerate from 10c to low teens to early 20c high teens. But the share price has been stuck there. No market buying interest for most of the reasons you have mentioned.

One would hope the with the data we have and results from competitors, finding a partner would be relatively easy. We have been told non dilutive finance was being persued. But then that went quiet.

We have another two weeks ish for another update re the trial approval. Previous announcements have hinted the trial could be started before the end of CY21. This means finance needs to be announced soon. Are we in the blackout period of the deal of the centry? Or is the share price being held low for the CR? Possibly the answer will be different for different people depending upon if the use their head or heart to make the decision.

It is frustrating to be so close to having the trial approved, and seeing the other indications that be investigated for the drug, but have the share price remain stagnant

I am keeping my eye on the prize. The science, from what has been published, seems sound. But I also agree with what Sam and others in the past have said. We need more exposure. We need to generate market interest.

Expand

maybe:
price being held down so CG and GP can get their options @ 18c. ….. 5,000 options each ?

ANP Price at posting: 19.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BC8

Black Cat Syndicate one pour away from being rerated as producer

IDA

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

There are more pages in this discussion • 24 more messages in this thread...

First 14 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.2¢		Change -0.003(4.00%)		Mkt cap ! $65.81M

Open	High	Low	Value	Volume
7.3¢	7.3¢	7.2¢	$16.52K	226.7K

Buyers (Bids)

No.	Vol.	Price($)
2	123420	7.2¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	8181	1

View Market Depth

No.	Vol.	Price($)
2	123420	0.072
2	310000	0.071
4	34299	0.070
2	28980	0.069
3	33055	0.068

Price($)	Vol.	No.
0.075	8181	1
0.077	147287	1
0.078	125476	3
0.079	175123	2
0.080	287231	3

Last trade - 10.49am 29/07/2024 (20 minute delay)

PER (ASX) Chart

maybe:price being held down so CG and GP can get their options @...

Black Cat Syndicate one pour away from being rerated as producer

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

maybe:price being held down so CG and GP can get their options @...

Top Stories

Black Cat Syndicate one pour away from being rerated as producer

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News